Evidence map›Paper›PMID 42902031›Full record

ArticleArchives of toxicology2026

PFAS:VDR interactions and immunotoxicity through disruption of monocyte differentiation.

Morgan Barnes, Joseph Lewis, Emily Banegas, Sean Ekins, Seth Kullman

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Morgan BarnesDepartment of Biological Sciences, North Carolina State University, Raleigh, NC, USA.
Joseph LewisDepartment of Biological Sciences, North Carolina State University, Raleigh, NC, USA.
Emily BanegasDepartment of Biological Sciences, North Carolina State University, Raleigh, NC, USA.
Sean EkinsCollaborations Pharmaceuticals Inc, Raleigh, NC, USA.
Seth KullmanDepartment of Biological Sciences, North Carolina State University, Raleigh, NC, USA. swkullma@ncsu.edu.ORCID http://orcid.org/0000-0002-6029-2266

Funding

NIEHS NIH HHS T32ES07046
6 · The paper itself

Abstract

Accumulating evidence indicates that per- and polyfluoroalkyl substances (PFAS) have the capacity to modulate vitamin D receptor (VDR) signaling however, the underlying mechanisms governing these interactions remain poorly understood. In the present study, we investigated direct interactions between PFAS and VDR signaling, as well as a novel, putative mechanism by which PFAS may induce immunotoxicity through disruption of VDR molecular functionalities. VDR is widely expressed across both the innate and adaptive branches of the immune system, where it plays critical roles in regulating immune cell activation, differentiation, and function. While PFAS exposure has been consistently associated with immune dysregulation and reduced vaccine responsiveness in both human and animal studies, the molecular basis of PFAS-induced immunotoxicity is only partially defined. To address these knowledge gaps, we examined a panel of PFAS compounds previously identified through computational modeling to possess measurable binding affinities for the VDR. We employed a suite of complementary, orthogonal bioassays to characterize the functional interactions between PFAS and the vitamin D receptor. These included a transient transactivation assay to assess global receptor agonist and antagonist activity, a Mammalian two-Hybrid (M2H) assay to evaluate PFAS effects on VDR interactions with its obligate heterodimerization partner (RXR), coactivator (SRC-1), and corepressor (NCoR1), and a THP-1 cell differentiation/transcription assay to probe the transcriptional consequences of PFAS exposure on vitamin D-facilitated monocyte cell differentiation. Collectively, our findings reveal that select PFAS engage in complex molecular interactions with the VDR and act as potent antagonists, effectively inhibiting vitamin D-mediated receptor function and downstream THP-1 cell signaling.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.